Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants During Three RSV Seasons
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Nirsevimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms Vakzimeter RSV
- Sponsors Sanofi
Most Recent Events
- 05 Jun 2025 Planned End Date changed from 25 Apr 2025 to 30 May 2026.
- 05 Jun 2025 Planned primary completion date changed from 25 Apr 2025 to 30 May 2026.
- 05 Jun 2025 Status changed from recruiting to active, no longer recruiting.